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Background: Ever since the 1996 revision of the Declaration of 
Helsinki, the World Medical Association has attempted to address 
ethical and scientific concerns of its diverse stakeholders for Articles 
33 (use of placebo) and 34 (posttrial provisions), most recently in 
2013. Both are inextricably linked to standard of care, an essential 
element of any comparative, interventional clinical trial. But has 
this now 20-year-long ethical debate truly been put to rest? The 
choice of standard of care in clinical trials remains a complex issue, 
particularly for comparative trials conducted in emerging countries. 
Interpretations of the Declaration of Helsinki as the cornerstone 
document for medical ethics range from best intervention available 
worldwide to any locally available standard of care for the compara-
tor group, which in the worst case could mean no interventional 
care at all.1,2
Objectives: Our aim was to examine the current status of clinical 
research practice and ethical guidance on standard of care, with a 
focus on international health research, and to review corresponding 
guidance issued by pharmaceutical sponsors in their publicly acces-
sible policies on clinical research.
Methods: We reviewed ethical recommendations before and after 
2013 and scientific literature, as well as major clinical trial registries 
(European Union, United States, and World Health Organization), 
to assess current clinical research practice related to standard of 
care. Furthermore, the websites of the top-ranked 25 pharmaceuti-
cal companies on sales figures in 20143 were reviewed for publicly 
accessible policies with reference to standard of care in clinical trials 
in emerging regions.
Results: After a period of active scientific-ethical debate before the 
2013 revision of the Declaration of Helsinki, few ethical discussions 
or recommendations have since been published that could provide 
additional guidance to clinical researchers. The recent scientific lit-
erature reflects the continued challenge for researchers to design 
an ethically and scientifically sound study, especially in vulnerable 
populations. However, ~20% of registered open clinical trials across 
major trial registries are designed with a placebo control, suggest-
ing that the question of standard of care remains highly pertinent. 
The review of pharmaceutical sponsor websites revealed a highly 
variable picture with regard to publicly available policies or state-
ments on this issue, particularly for research conducted in low- to 
middle-income countries. The review outcome spans results from 
any policy published to very clearly worded statements on clinical 
research in developing countries, the standard of care aspect dur-
ing the trial conduct, and regulatory strategies after completion of 
product development.
Conclusions: Investigators, ethics committees, and sponsors continue 
to be confronted with the challenge of ensuring ethically and scien-
tifically sound clinical studies with appropriate standard of care. We 
have attempted to examine available ethical guidance and summarize 
recommendations for clinical trial designs that could assist in address-
ing these challenges. Care should be taken to maintain a high level 
of awareness for the importance of a sound ethical framework for a 
scientifically valid clinical trial design. Pharmaceutical companies, as 
major sponsors of clinical research, should demonstrate awareness and 
an appropriate management of these aspects, particularly in regions 
with limited resources. As part of the ongoing debate on transparency, 
one option could be to formulate positions and make them available to 
the public, regardless of whether such a statement is legally required. 
A few examples already exist where such clarifying statements have 
been provided. This approach would prepare the ground for an open 
and transparent communication to agencies, ethics committee, and, 
last but not least, patients.
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